

Hepatitis C Virus

Patient Information		Prescriber + Shipping Information			
Patient name: _____ DOB: _____ Sex: ☐ Female ☐ Male SSN: _____ Ethnicity: _____ Language: _____ Wt: _____ kg ☐ lbs Ht: _____ cm ☐ in Address: _____ Apt/Suite: _____ City: _____ State: _____ Zip: _____ Phone: _____ Alternate: _____ Caregiver name: _____ Relation: _____ Local pharmacy: _____ Phone: _____ Insurance plan: _____ Plan ID: _____ Please fax a copy of front and back of the insurance card(s).		Prescriber name: _____ NPI: _____ Address: _____ Apt/Suite: _____ City: _____ State: _____ Zip: _____ Contact: _____ Phone: _____ Alternate: _____ Fax: _____ Email: _____ If shipping to prescriber: ☐ First Fill ☐ Always ☐ Never			
Clinical Information (Please fax pertinent clinical and lab information)					
Diagnosis: ☐ B18.2 (Chronic Hepatitis C Virus) Diagnosis date: _____ Genotype: ☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 Subtype: ☐ A ☐ B ☐ A/B ☐ N/A Baseline viral load: _____ Date: _____ Degree of fibrosis: ☐ F0 ☐ F1 ☐ F2 ☐ F3 ☐ F4 ☐ _____ Cirrhosis: ☐ None ☐ Compensated ☐ Decompensated (CTP: ☐ B ☐ C) Co-infection(s): ☐ None ☐ HIV ☐ HBV		Transplant status: ☐ N/A ☐ Pre-transplant ☐ Post-transplant sCr: _____ GFR: _____ Date: _____ CKD stage: ☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ N/A Dialysis: ☐ Yes ☐ No IL28B polymorphism: ☐ CC ☐ CT ☐ TT Q80K polymorphism: ☐ Yes ☐ No NS5A polymorphism: ☐ Yes ☐ No NS5A polymorphism type: ☐ M28 ☐ Q30 ☐ L31 ☐ Y93 ☐ _____			
Prior Regimen ☐ Naïve ☐ Experienced (List below) _____ _____	Start Date _____ _____	End Date _____ _____	Treatment Weeks _____ _____	Response* ☐ IC ☐ NR ☐ PR ☐ RLP ☐ IC ☐ NR ☐ PR ☐ RLP ☐ IC ☐ NR ☐ PR ☐ RLP	
<i>*Response definitions: IC – Incomplete treatment, NR – Null Responder, PR – Partial Response, RLP – Relapser</i>					
Comorbidities: _____ Concomitant Medications: _____ Allergies: ☐ NKDA ☐ Other: _____					
Prescription	Quantity	Duration	Refill		
☐ Daklinza® (daclatasvir)	☐ Take 30 mg by mouth once daily ☐ Take 60 mg by mouth once daily ☐ Take 90 mg by mouth once daily	☐ 28 x 30 mg tablets ☐ 28 x 60 mg tablets ☐ 28 x 90 mg tablets	☐ 12 weeks ☐ 24 weeks	☐ _____	
☐ Epclusa® (velpatasvir/sofosbuvir)	☐ Take 100 mg/400 mg by mouth once daily	☐ 28 x 100 mg/400 mg tablets	☐ 12 weeks ☐ 24 weeks	☐ _____	
☐ Harvoni® (ledipasvir/sofosbuvir)	☐ Take 90 mg/400 mg by mouth once daily	☐ 28 x 90 mg/400 mg tablets	☐ 8 weeks ☐ 12 weeks ☐ 24 weeks	☐ _____	
☐ Olysio® (simeprevir)	☐ Take 150 mg by mouth once daily	☐ 28 x 150 mg capsules	☐ 12 weeks ☐ 24 weeks	☐ _____	
☐ Sovaldi® (sofosbuvir)	☐ Take 400 mg by mouth once daily	☐ 28 x 400 mg tablets	☐ 12 weeks ☐ 24 weeks	☐ _____	
☐ Technivie™ (ombitasvir/paritaprevir/ritonavir)	☐ Take 2 tablets by mouth in the morning with food	☐ 56 x 12.5 mg/75 mg/50 mg tablets	☐ 12 weeks ☐ 24 weeks	☐ _____	
☐ Viekira Pak® (dasabuvir/ombitasvir/paritaprevir/ritonavir)	☐ Take 3 tablets by mouth in the morning and 1 tablet by mouth in the evening with food	☐ 112 x 250 mg/12.5 mg/75 mg/50 mg tablets	☐ 12 weeks ☐ 24 weeks	☐ _____	
☐ Viekira XR™ (dasabuvir/ombitasvir/paritaprevir/ritonavir)	☐ Take 3 tablets by mouth once daily with food	☐ 84 x 200 mg/8.33 mg/50 mg/33.33 mg tablets	☐ 12 weeks ☐ 24 weeks	☐ _____	
☐ Zepatier™ (elbasvir/grazoprevir)	☐ Take 50 mg/100 mg by mouth once daily	☐ 28 x 50/100 mg tablets	☐ 12 weeks ☐ 16 weeks	☐ _____	
☐ Pegasys® (peginterferon alfa-2a)	☐ Inject 180 mcg subcut once weekly ☐ _____	☐ 4 x 180 mcg	☐ PFS ☐ Autoinjector	☐ _____	
☐ Ribasphere® Ribapak® Dose Pak (ribavirin)	☐ Take _____ mg tablet by mouth every morning, _____ mg tablet by mouth every evening (_____ mg/day)	☐ 28 x 200 mg; 28 x 400 mg ☐ 28 x 400 mg; 28 x 400 mg ☐ 28 x 400 mg; 28 x 600 mg ☐ 28 x 600 mg; 28 x 600 mg	Tablets	☐ _____	
☐ Moderiba™ Dose Pack (ribavirin)	☐ Take _____ mg tablet by mouth every morning, _____ mg tablet by mouth every evening (_____ mg/day)	☐ _____ x 200 mg	☐ Tablets ☐ Capsules	☐ _____	
**For the form (tablets or capsules), unless otherwise specified, pharmacy preference/availability (or insurance preference) will be dispensed.					
Per state-specific law, prescriptions will be dispensed as generic, if applicable, unless notated otherwise: _____					
Prescriber's Signature: _____ Date: _____					
I authorize Corexa Health Pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization and appeal process for this prescriptions and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice Corexa Pharmacy.					
Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling 444-277-4276 or by emailing info@comsprx.com is to obtain instructions as to the proper destruction of the transmitted material. Thank you.					